TCAP gene is not a common cause of cardiomyopathy in Iranian patients

Zahra Alaei1,2, Nasrin Zamani2,3, Bahareh Rabbani3

  • 1Faculty of Basic Sciences, Islamic Azad University, East Tehran Branch, Tehran, Iran.

PubMed

Insights

Pathogenic mutations in the TCAP gene are not a common cause of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) in Iranian patients. However, TCAP gene variants are linked to various conditions, including LGMD-2G, HCM, and DCM.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Genetic Medicine

Background:

  • Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are leading causes of heart failure and sudden cardiac death.
  • Genetic variants in Z-disc proteins, including telethonin (TCAP), are implicated in DCM and HCM etiology.
  • TCAP gene mutations are associated with various neuromuscular and cardiac conditions.

Purpose of the Study:

  • To investigate the role of the TCAP gene in Iranian patients diagnosed with cardiomyopathies.
  • To identify novel pathogenic or likely pathogenic variants in the TCAP gene within this population.
  • To review existing literature on TCAP gene variants and their associated phenotypes.

Main Methods:

  • Genetic analysis of the TCAP gene in 40 unrelated Iranian patients with HCM or DCM.
  • In-silico analysis to predict the pathogenicity of identified variants.
  • Comprehensive literature and database review of reported TCAP gene variants.

Main Results:

  • Only one intronic variant (c.111-42G>A) was found in an HCM patient, predicted as polymorphism.
  • Literature review revealed 44 TCAP gene variants, predominantly missense mutations.
  • TCAP mutations are linked to limb-girdle muscular dystrophy 2G (LGMD-2G), DCM, HCM, and other conditions, with LGMD-2G being the most frequent phenotype.

Conclusions:

  • TCAP gene mutations appear uncommon as a cause of cardiomyopathy in the studied Iranian cohort.
  • TCAP gene variants can manifest in diverse clinical presentations, notably LGMD-2G, HCM, and DCM.
  • Further research may be needed to fully elucidate the TCAP gene's contribution to cardiomyopathies in diverse populations.
Abstract

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
15
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
190